Baxter offers a variety of medical supplies and equipment to providers... Show more
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| VIC.X | 0.003179 | -0.000044 | -1.37% |
| Viction cryptocurrency | |||
| LRC.X | 0.007164 | -0.000236 | -3.19% |
| Loopring cryptocurrency | |||
| ZEC.X | 1207.651500 | -52.558960 | -4.17% |
| Zcash cryptocurrency | |||
| AXS.X | 0.786223 | -0.043382 | -5.23% |
| Axie Infinity cryptocurrency | |||
| PEOPLE.X | 0.005684 | -0.000347 | -5.75% |
| ConstitutionDAO cryptocurrency | |||
A.I.dvisor indicates that over the last year, BAX has been loosely correlated with ICUI. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if BAX jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To BAX | 1D Price Change % | ||
|---|---|---|---|---|
| BAX | 100% | +0.55% | ||
| ICUI - BAX | 56% Loosely correlated | +2.66% | ||
| LUNG - BAX | 53% Loosely correlated | N/A | ||
| STE - BAX | 51% Loosely correlated | -0.72% | ||
| SYK - BAX | 51% Loosely correlated | -2.75% | ||
| BDX - BAX | 49% Loosely correlated | -0.78% | ||
More | ||||
| Ticker / NAME | Correlation To BAX | 1D Price Change % |
|---|---|---|
| BAX | 100% | +0.55% |
| Pharmaceuticals: Other industry (49 stocks) | 62% Loosely correlated | +2.81% |
| Pharmaceuticals industry (152 stocks) | -2% Poorly correlated | +1.60% |
a provider of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices
Industry PharmaceuticalsOther
The 10-day RSI Indicator for BAX moved out of overbought territory on October 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 instances where the indicator moved out of the overbought zone. In 25 of the 32 cases the stock moved lower in the days that followed. This puts the odds of a move down at 78%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on BAX as a result. In 45 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Moving Average Convergence Divergence (MACD) for BAX just turned positive on November 04, 2026. Looking at past instances where BAX's MACD turned positive, the stock continued to rise in 19 of 46 cases over the following month. The odds of a continued upward trend are 41%.
BAX moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BAX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +9.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where BAX advanced for three days, in 166 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
BAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 146 of 210 cases where BAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. BAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 68 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.148) is normal, around the industry mean (4.964). P/E Ratio (-12.459) is within average values for comparable stocks, (40.591). BAX's Projected Growth (PEG Ratio) (36.677) is very high in comparison to the industry average of (4.143). Dividend Yield (0.002) settles around the average of (0.005) among similar stocks. P/S Ratio (1.057) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.